



## 1st quarter 2017 revenue

€197.3 million at constant exchange rates, up 7.4%

### Confirmation of the trend that started in the fourth quarter of 2016

**Villepinte, April 27, 2017 - Guerbet** (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing revenue of €203.1 million for the 1st quarter of 2017, up by 10.5% at current exchange rates (7.4% at constant exchange rates) compared with the same period last year.

#### Consolidated Group revenue (IFRS)

In millions of euros at March 31, 2017	Change (%)	2017 at current exchange rates	Change (%)	2017 at constant exchange rates	2016
Sales in Europe	+1.1%	94.3	+2.2%	95.3	93.2
Sales in Other Markets	+20.3%	108.8	+12.7%	102.0	90.5
<b>Total 1st quarter revenue</b>	<b>+10.5%</b>	<b>203.1</b>	<b>+7.4%</b>	<b>197.3</b>	<b>183.7</b>

Activity is growing in Europe and in the Other Markets. The 1st quarter 2017 revenue in Europe totaled €95.3 million, up 2.2% at constant exchange rates, given the now effective prioritization of product/market pairings (for X-rays in particular). Sales are still growing strongly in the Other Markets, especially in Asia, a priority development zone for the Group, as well as in the US and Latin America, and particularly Brazil.

At constant exchange rates, activity grew in every segment:

- The **MRI** segment reported revenue of €65.6 million, representing a 10.4% increase, thanks to steady sales of Dotarem® in the US
- The **X-ray** segment rose by 4.2% to €94.5 million, particularly due to the excellent performance of Optiject®

## Press release

- Sales were stable in the **IRT** segment at €12.1 million (+0.9%)
- The **Imaging Solutions and Services (ISS)** segment gained considerable ground (+27.5%) with revenue of €20.0 million, confirming the trend that started at the end of 2016.

### Outlook for 2017: return to growth

In less than eighteen months, the declining sales of the business acquired at the end of 2015 were strategically turned around. The strong performance in the 1st quarter of 2017 for all four product segments reflects this success achieved and gives a confidence boost to the Group, which is confirming its full-year growth target.

## Upcoming events: Publication of H1 2017 revenue July 27, 2017, after trading

### About Guerbet

---

Guerbet is a pioneer in the contrast agent field, with 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on Euronext Paris (Segment B – Mid Caps) and generated €776 million in revenue in 2016.

For more information about Guerbet, please visit [www.guerbet.com](http://www.guerbet.com)

### Contacts

---

#### **Guerbet**

**Jean-François Le Martret**  
Chief Financial Officer  
(+33)(0)1 45 91 50 00

#### **Actifin**

Financial Communications  
**Benjamin Lehari**  
(+33)(0)1 56 88 11 25  
[blehari@actifin.fr](mailto:blehari@actifin.fr)

Press  
**Jennifer Jullia**  
(+33)(0)1 56 88 11 19  
[jjullia@actifin.fr](mailto:jjullia@actifin.fr)